Company Overview
Hoth Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapies designed to address significant unmet medical needs within the healthcare sector. The company specifically focuses on advancing HT-001, a topical formulation that is currently undergoing Phase II clinical trials for the treatment of patients experiencing rash and skin disorders associated with initial and repeat courses of therapy. This entity functions within the biotechnology industry, a domain characterized by high research and development expenditures and a reliance on successful clinical trial outcomes to generate future revenue streams. With a market capitalization of $12.50M and an employee count of 2, the company represents a micro-cap asset with a very small operational footprint. The minimal market cap and the absence of reported annual revenue figures indicate that the company is in a pre-revenue or early-stage development phase, where value is derived primarily from intellectual property and clinical progress rather than current sales performance.
Financial Health
The company reports no revenue over the trailing twelve-month period, while recording a net income loss of $-11,883,703 and an EBITDA figure that is not available. The substantial gap between the reported zero revenue and the significant net income loss of $-11,883,703 reveals a cost structure dominated by research and development expenses, operational overhead, and likely clinical trial costs that have not yet been offset by sales. Free cash flow stands at $-6,641,136, indicating that the company is burning cash to fund its operations and development pipeline rather than generating liquidity from its current business activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which reflects the typical financial profile of a clinical-stage biotechnology firm that has not yet achieved commercial product sales to generate positive gross revenue or operational profitability. Regarding liquidity and leverage, the company holds $7.85M in cash against a negligible debt position of $13,599, resulting in a debt-to-equity ratio of 0.17. This balance sheet structure suggests a highly conservative approach to leverage, as the company possesses sufficient cash reserves to cover its minimal debt obligations many times over. The current ratio is listed at 8.81, a figure that indicates strong short-term liquidity relative to current liabilities, providing ample flexibility to fund ongoing clinical trials and operational needs without immediate refinancing pressures. Return on Equity is calculated at -151.1% and Return on Assets at -84.5%, metrics that reveal the company is currently destroying equity and assets value through its investment in clinical development rather than generating returns for shareholders. These negative return metrics are characteristic of early-stage biotechs where capital is heavily deployed before any commercial return is realized.
Valuation Assessment
Trailing P/E and forward P/E ratios are presented as N/A and -1.13 respectively, implying that the earnings trajectory is currently negative and does not support a traditional multiple-based valuation based on historical profitability. The price-to-book ratio is 1.48, suggesting that the market is valuing the company at a premium of 48% over its net asset book value, likely due to the intangible value of its intellectual property and clinical-stage assets. Price-to-sales ratio and EV/EBITDA are both listed as N/A, which indicates that standard valuation multiples derived from sales or earnings power are not applicable due to the lack of revenue and earnings data. The stock has exhibited volatility within a 52-week range bounded by a high of $2.12 and a low of $0.66, with the current trading price situated within this band. A beta of 0.55 indicates that the stock's price volatility is significantly lower than the broader market, moving at roughly 45% of the market's amplitude, which offers a distinct risk profile compared to high-beta biotechnology peers. The forward P/E of -1.13 further underscores the speculative nature of the valuation, as negative multiples are only meaningful in the context of anticipated future earnings that have not yet materialized.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both reported as N/A, preventing a direct comparison of earnings growth versus revenue growth rates at this stage of the company's lifecycle. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the entity reinvests all available capital, including its cash reserves, into research and development and clinical trial activities rather than distributing income to shareholders. Since the company is not a dividend payer, the growth profile is entirely dependent on the successful progression of HT-001 through clinical trials and eventual regulatory approval to transition from a clinical-stage entity to a commercial product. The overall growth and income profile is currently defined by high cash burn and zero current income generation, placing the total return potential exclusively in the hands of successful future commercialization events.